Figure 3
Antitumor activity of lenvatinib against the KP-1/VEGF and KP-1/FGF transfectants in nude mice. Lenvatinib was administered orally twice daily, when tumor volumes reached approximately 200 mm3(A,C,D). Each group consisted of 5 mice. Data are the mean ± std. *p < 0.05 compared to vehicle. (A-C) the KP-1/VEGF xenograft model. (D) the KP-1/FGF xenograft model. (A) Antitumor activity of lenvatinib against KP-1/VEGF xenografts. Lenvatinib was administered at 1–100 mg/day for 14 days. Tumor tissues were resected on day 26 for IHC analysis. Tumor vessels were stained with anti-mouse CD31 antibody. Photographs were taken using a light microscope (x25) and representative images are shown. (B) Antitumor activity of lenvatinib in the advanced KP-1/VEGF xenograft model. Lenvatinib was administered at 100 mg/kg for either 14, 18 or 14 days, when the tumor size reached 150, 650 and 1000 mm3, respectively. (C) Antitumor activity of lenvatinib with an interval of treatments. Lenvatinib was administered at 100 mg/kg for 14 days in the 1st cycle and again given for 10 days in a 2nd cycle with 11 days interval between the 1st and 2nd cycles. (D) Antitumor activity of lenvatinib in the KP-1/FGF xenograft model. Lenvatinib was administered at 30 and 100 mg/kg for 14 days.